Daria Olena Berger

Daria Olena Berger

Auto-generated profile, based on publicly available information

Daria Olena Berger

Univ Bern, Inst Social & Prevent Med, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
MBMaximus Berger
Maximus Berger
AKAnn Katrin Kraeuter
Ann Katrin Kraeuter
DRDaria Romanik
Daria Romanik
PMPeter Malouf
Peter Malouf
GAG. Paul Amminger
G. Paul Amminger
Zoltan SarnyaiZoltan Sarnyai
Zoltan Sarnyai

10 November 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
AMAnne Munck
Anne Munck
DBDaria O Berger
Daria O Berger
KSKevin W Southern
Kevin W Southern
CCcarla carducci
carla carducci
KGKarin M de Winter-De Groot
Karin M de Winter-De Groot
MSMoat Stuart
Moat Stuart

23 April 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EPEva Sophie Lunde Pedersen
Eva Sophie Lunde Pedersen
Carmen De JongCarmen De Jong
Carmen De Jong
MJM Jurca
M Jurca
DBDo Berger
Do Berger
JSJavier Sanz
Javier Sanz
CRCs Rueegg
Cs Rueegg

30 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
DBDaria Olena Berger
Daria Olena Berger
EPEva S L Pedersen
Eva S L Pedersen
MMMaria Christina Mallet
Maria Christina Mallet
CJCarmen C M de Jong
Carmen C M de Jong
JUJakob Usemann
Jakob Usemann
TTthe SPAC Study Team
the SPAC Study Team
Rationale: The Predicting Asthma Risk in Children (PARC) tool uses questionnaire-based respiratory symptoms collected from preschool children to predict their risk of asthma 5 years later. The tool was originally developed and externally validated in population-based settings and has not yet been validated in a clinical setting. Objective: To externally validate the PARC tool in children seen in paediatric pulmonology clinics. Methods: The Swiss Paediatric Airway Cohort (SPAC) is a prospective study of children seen in respiratory outpatient clinics across Switzerland. This analysis included children seen at ages 1-6 years for cough or wheeze at baseline and who completed the follow-up questionnaire 2 years later. The outcome was defined as current wheeze plus use of asthma medication. In sensitivity analyses, we explored effects of varied inclusion criteria and outcomes. We assessed performance by describing sensitivity, specificity, negative and positive predictive value (NPV, PPV), area under the curve (AUC), scaled Brier’s score and Nagelkerke’s R 2 scores and compared performance in SPAC to that achieved in the original population, the Leicester Respiratory Cohort (LRC). Results: Among the 346 children included, 125 (36%) reported the outcome after 2 years. At a PARC score cut-off of 4, sensitivity was higher (95% vs 79%) but specificity lower (14% vs 57%) in SPAC compared to LRC. NPV was comparable (0.84 vs. 0.87) as was PPV (0.37 vs.0.42). Discrimination was lower in SPAC (AUC of 0.71 vs 0.78), as were Nagelkerke’s R 2 (0.18 vs 0.28) and scaled Brier’s scores (0.13 vs 0.22). When the outcome was changed to moderately severe asthma (>4 attacks plus use of asthma medication), there were improvements in AUC (0.74), sensitivity (0.97), specificity (0.22) and NPV (0.99), but some deterioration in PPV (0.13), R 2 (0.15) and scaled Brier score (0.09). Conclusion: While the PARC tool performs well in a population-based setting and has some clinical utility, in particular for ruling out the development of asthma, this study highlights the need for new prognostic prediction tools to be developed specifically for the clinical setting. Funding: SNSF:320030_182628, SLA2019-03_641670